A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry

Hepatol Int. 2017 Sep;11(5):440-445. doi: 10.1007/s12072-017-9809-y. Epub 2017 Jul 11.

Abstract

Background and aims: Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. Although direct-acting antivirals can cure the large majority of treated patients, important limitations remain, including treatment failure and high costs precluding access to therapy in resource-limited settings. We report herein the anti-HCV effects of IND02, a procyanidin type A molecule, isolated and characterized from cinnamon.

Methods and results: Using cellculture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and subgenomic replicons, we demonstrated that IND02 markedly and dose-dependently inhibited HCV cell entry. Kinetic assays demonstrated that IND02 inhibits HCV entry most likely at a postbinding step. Experiments performed using primary human hepatocytes confirmed inhibition of HCV entry by IND02, demonstrating the functional impact in the most physiological cell-based system for studying HCV-host interactions.

Conclusions: The natural compound IND02 exhibits potent HCV cell entry inhibition and provides a novel perspective for development of a low-cost antiviral for treatment of HCV infection.

Keywords: Antiviral; Hepatitis C; IND02; Infection; Liver.

MeSH terms

  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Biflavonoids / pharmacology*
  • Biflavonoids / therapeutic use
  • Catechin / pharmacology*
  • Catechin / therapeutic use
  • Cinnamomum zeylanicum*
  • Dose-Response Relationship, Drug
  • Hepacivirus / drug effects*
  • Hepacivirus / physiology
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Proanthocyanidins / pharmacology*
  • Proanthocyanidins / therapeutic use

Substances

  • Antiviral Agents
  • Biflavonoids
  • Proanthocyanidins
  • procyanidin
  • Catechin